Summary & Overview
HCPCS Level II C9300: Injection, Indigotindisulfonate Sodium, 1 mg
HCPCS Level II code C9300 denotes the injection of indigotindisulfonate sodium, 1 mg, used for diagnostic or therapeutic purposes where a measured parenteral dose is required. Nationally, codes for injectable agents are important for billing accuracy, cost transparency, and tracking use of specialized diagnostic drugs. HCPCS Level II codes like C9300 facilitate consistent reporting across outpatient clinics, hospital outpatient departments, and physician offices.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for this injectable agent, typical sites of service, and the payer landscape covered. The publication outlines billing and coding considerations for the drug administration service line, summarizes common modifiers applicable to this code, and highlights areas where policy updates or payer-specific coverage rules may affect claim adjudication.
The analysis provides benchmarks and policy-relevant information to aid coding professionals, practice managers, and billing analysts in understanding reimbursement pathways, documentation expectations, and payer engagement strategies for HCPCS Level II code C9300. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9300 describes Injection, indigotindisulfonate sodium, 1 mg. The service represented is a drug administration of a diagnostic or therapeutic injectable agent provided as a measured dose of indigotindisulfonate sodium. The typical site of service for this injectable medication is an outpatient clinic, hospital outpatient department, or physician office where parenteral injections and diagnostic agents are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing diagnostic evaluation for suspected sentinel lymph node mapping or cutaneous lesion localization during oncology surgery or dermatologic procedures. The clinician prepares a measured dose of indigotindisulfonate sodium for intraoperative injection to visually delineate lymphatic channels or mark lesion margins. The workflow includes pre-procedure consent, verification of dye allergies (particularly sulfonamide sensitivity), aseptic preparation, administration of the indicated mg dose at the lesion site or peritumoral/peri-areolar region, and immediate intraoperative visualization by the surgical team. Post-injection monitoring focuses on immediate hypersensitivity reaction surveillance and documentation of injection site and lot number in the operative record. Typical settings include hospital outpatient surgery, ambulatory surgery centers, and specialty clinics where surgical mapping or lymphatic visualization is performed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or complexity for injection or associated procedure is substantially greater than typical (document rationale). |
23 |